Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing (Quarter Ended

Vyome Holdings Announces Transformational First

Following Nasdaq Listing

(Quarter Ended September 30, 2025)

Cambridge, Mass: Vyome Holdings, Inc., ("Vyome")

(NASDAQ: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its

financial results and a series of corporate and clinical milestones following its successful listing on Nasdaq.

This quarter marks Vyome's first full reporting period as a newly

listed Nasdaq company. Vyome is a clinical-stage, and AI-focused company positioned to accelerate development across immuno-inflammatory

and potential orphan indications.

"Vyome is targeting one of the biggest challenges in the world

today - inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with

a laser focus on shareholder value, whether it's our capital structure, the development of our assets, or looking at AI opportunities,"

said Krishna Gupta, Chairman of Vyome. "We had a great first quarter as a public company thanks to our unique strengths, including

expertise in/access to the US-India innovation corridor. We announced an important interim result for our drug targeting the billion-dollar

opportunity in malignant fungating wound (MFW), and it's just the beginning!"

"This quarter marks a defining step forward for Vyome. We executed

a highly efficient transition to the public markets, spending less cash than expected in our first quarter as a public company and strengthening

our organization while advancing our lead program," noted Venkat Nelabhotla, CEO of Vyome. He further added, "The promising

interim Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations,

clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for

both shareholders and patients."

VT-1953: Highly Encouraging Interim Phase 2 study Readouts

The lead program, VT-1953, a topical agent targeting symptoms of putrid

smell and pain in malignant fungating wounds (MFW), an inflammatory condition afflicting an estimated one million cancer patients, continued

to show strong clinical momentum.

MFW is a devastating condition affecting 5-14% of advanced cancer

patients, often leading to severe emotional and social burden due to an extremely bad smell, which prevents any interaction with family

or friends. MFW represents a potential addressable market opportunity of $1B in the USA with no FDA-approved drug; VT-1953 would be the

only solution on the market. VT-1953 is being advanced as a potential orphan drug candidate, with full data of Phase 2 readouts expected

to be announced in the first week of December 2025.

We previously reported strong preclinical efficacy for VT-1908 eye

drops in uveitis models in the third quarter, reinforcing its promise as a highly needed steroid-sparing candidate. FDA interactions for

VT-1908 are planned for the first half of 2026, alongside continued development activities to advance the program towards clinical readiness.

Third Quarter 2025 Financial Summary

Clean Capital Structure

The Company will host a conference call

and webcast on Thursday, November 20, at 10:00 a.m. ET to discuss the results. To access the webcast, please use the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=PzMQuQGB or

dial in at 877-407-5795 (U.S. toll-free) / +1 201-689-8722 (international).

A replay will be available on the Company

About Vyome Holdings, Inc.:

Vyome is building the world's premier platform spanning the US-India

innovation corridor. Vyome's immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with

immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor,

Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and

To learn more, please visit www.vyometx.com

Forward-Looking Statements

Certain statements made in this press release are "forward-looking

statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements may be identified by the use of words such as "target," "believe," "expect,"

"will," "shall," "may," "anticipate," "estimate," "would," "positioned,"

"future," "forecast," "intend," "plan," "project," "outlook",

and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such

statements include, but are not limited to, statements contained in this press release relating to Vyome's business strategy, Vyome's

future operating results, and liquidity and capital resources outlook. Forward-looking statements are based on Vyome's current expectations

and assumptions regarding Vyome's business, the economy, and other future conditions. Because forward-looking statements relate

to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Vyome's

actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical

fact nor guarantees of assurance of future performance. Vyome cautions you, therefore, against relying on any of these forward-looking

statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include,

without limitation, Vyome's ability to raise capital to fund continuing operations; our ability to protect Vyome's intellectual

property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and

products; Vyome's ability to develop and commercialize products and services; changes in government regulation; Vyome's ability

to complete capital raising transactions; and other factors relating to Vyome's industry, operations and results of operations.

Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events

that could cause Vyome's actual results to differ may emerge from time to time, and it is not possible for Vyome to predict all

of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update

any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as

may be required under applicable securities law.

Visit us on social media:

SUMMARY FINANCIAL STATEMENTS

SUMMARY OF CONSOLIDATED BALANCE SHEETS AS OF,

SUMMARY OF CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE